The Drug That Quiets Your Appetite May Also Quiet Your Nose

A new study in JAMA Otolaryngology–Head & Neck Surgery (June 25, 2026) reports that adults with type 2 diabetes taking a GLP-1 receptor agonist were roughly 48% more likely to be diagnosed with a smell or taste disturbance than matched patients on a different diabetes drug. The headline number is real. So is the part most coverage buried: the absolute risk is tiny, the study can't prove cause, and a separate body of work says these same drugs sometimes sharpen the senses they're now accused of dulling. The interesting story is the contradiction, and what it tells us about where GLP-1 drugs actually act.